IL1B and myocardial infarction: The CANTOS (Anti-inflammatory therapy with canakinumab for atherosclerotic disease) trial, a phase III randomized double-blind placebo-controlled study, investigated the effects of canakinumab, an anti-IL-1β monoclonal antibody, in 10,061 patients with previous myocardial infarction (MI) and hs-CRP > 2 mg/L.